Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain

Pediatric Blood and Cancer

Volumn 58, Issue 2, 2012, Pages 300-302

  Yamada, Kayo ^a   Yasui, Masahiro ^a   Sawada, Akihisa ^a   Inoue, Masami ^a   Nakayama, Masahiro ^a   Kawa, Keisei ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

2 chlorodeoxyadenosine; Allogeneic hematopoietic stem cell transplantation; Cladribine; Juvenile xanthogranuloma; Myelosuppression; Reduced intensity conditioning

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; PREDNISOLONE; PREDNISONE; TACROLIMUS; VINCRISTINE;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CHILD; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE INCREASE; GAMMA KNIFE RADIOSURGERY; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INFECTION; JUVENILE XANTHOGRANULOMA; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR REGRESSION;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BRAIN DISEASES; CHILD; CLADRIBINE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROGNOSIS; RECURRENCE; XANTHOGRANULOMA, JUVENILE;

EID: 83455253774     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23087     Document Type: Article

References (15)

1. Saven A, Piro LD. 2-Chlorodeoxyadenosine: A potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol Cell Ther 1996; 38: 93-101.
2. Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 247-258.
3. Orsey A, Paessler M, Lange BJ, et al. Central nevous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50: 927-930.
4. Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA(cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43: 81-84.
5. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patiens with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2008; 50: 72-79.
6. Mottl H, Stary J, Chanova M, et al. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymphoma 2006; 47: 1881-1884.
7. Rajendra B, Duncan A, Parslew R, et al. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009; 52: 413-415.
8. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-2448.
9. Santana VM, Mirro J, Jr, Harwood FC, et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991; 9: 416-422.
10. Beutler E, Koziol JA, McMillan R, et al. Marrow suppression produced by repeated doses of cladribine. Acta Haematol 1994; 91: 10-15.
11. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41: 2682-2689.
12. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-743.
13. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-2460.
14. Van Den Neste E, Louviaux I, Michaux JL, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2-deoxyadenosine. Br J Haematol 1999; 105: 268-270.
15. Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011; 46: 77-83.